Open-angle Glaucoma Clinical Trial
Official title:
Waveform Analysis of the Doppler Curve of Ophthalmic Arteries in Primary Open-angle and Normal Tension Glaucoma Patients
Color Doppler Imaging (CDI) has been providing information about ocular blood flow over the
past decades. This non-invasive procedure based on ultrasound technique has identified
increased resistance and decreased systolic blood velocities to exist in the ophthalmic
arteries of glaucoma patients. However, existing data has provided very little information
regarding the analysis of the Doppler waveform in itself and to whether variables such as
early systolic acceleration or systolic/diastolic velocity ratios are of any significance in
glaucoma disease. In other medical specialties using CDI technology, such as nephrology or
cardiology for instance, this analysis has been part of the normal routine. This information
has been used in screening patients for disturbed circulation such as arterial stenosis or
providing information regarding prognosis of renal and hepatic transplants have been used
for decades now.
What is the normal characteristics of the waveform Doppler analysis? To answer this, the
investigators will create a normative database using healthy controls.
Are there signs of altered stiffness or compliance in the ophthalmic arteries of glaucoma
patients? To answer this, the analysis of early acceleration acceleration and detection of
an early peak systolic will be done on the Doppler curves of glaucoma patients and compared
to the healthy normative database.
Are there any difference between the two types of glaucoma [primary open-angle glaucoma
(POAG) and normal-tension glaucoma (NTG)]? The investigators will compare the variables of
the ophthalmic artery waveform in these two groups.
Do any of these Doppler waveform variables have any clinical significance? To answer this,
the investigators will search for the existence of any correlation between the waveform data
and both functional (visual field testing) and structural (Confocal scanning laser
ophthalmoscopy - CSLO) variables of the glaucoma groups.
1. Color Doppler imaging of the ophthalmic artery will be performed 2. Visual field testing will be done 2. CSLO will be done ;
Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01157364 -
Safety and Efficacy of a New Ophthalmic Formulation of Bimatoprost in Patients With Open Angle Glaucoma and Ocular Hypertension
|
Phase 1/Phase 2 | |
| Completed |
NCT02558374 -
Double-masked Study of Netarsudil (AR-13324) Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension
|
Phase 3 | |
| Completed |
NCT01444040 -
Subjects With Open-angle Glaucoma, Pseudoexfoliative Glaucoma, or Ocular Hypertension Naïve to Medical and Surgical Therapy, Treated With Two Trabecular Micro-bypass Stents (iStent Inject) or Travoprost
|
Phase 4 | |
| Completed |
NCT01415401 -
Efficacy and Tolerability of AZARGA® as Replacement Therapy in Patients on COMBIGAN® Therapy in Canada
|
Phase 4 | |
| Completed |
NCT01456390 -
Open-Angle Glaucoma Subjects With One Prior Trabeculectomy Treated Concurrently With One Suprachoroidal Stent and Two Trabecular Micro-bypass Stents
|
N/A | |
| Completed |
NCT01340014 -
Patient Preference Comparison of AZARGA Versus COSOPT
|
Phase 4 | |
| Completed |
NCT01455467 -
Open-angle Glaucoma Subjects on One Topical Hypotensive Medication Randomized to Treatment With One or Two Trabecular Micro-bypass Stents in Conjunction With Cataract Surgery
|
N/A | |
| Completed |
NCT01443988 -
Subjects With Open-angle Glaucoma, Pseudoexfoliative Glaucoma, or Ocular Hypertension Naïve to Medical and Surgical Therapy, Treated With Two Trabecular Micro-bypass Stents (iStent)or Travoprost
|
Phase 4 | |
| Completed |
NCT01426867 -
A Comfort Study of Brinzolamide 1% / Brimonidine 0.2% Fixed Combination, Brinzolamide 1% and Brimonidine 0.2%
|
Phase 2 | |
| Completed |
NCT01444105 -
Open-angle Glaucoma Subjects on One Ocular Hypotensive Medication Randomized to Treatment With Two Trabecular Micro-bypass Stents or Selective Laser Trabeculoplasty
|
N/A | |
| Completed |
NCT00759239 -
Phase IV Randomised Double-masked Clinical Trial: Assessing Morning Versus Evening Dosing of a Fixed Dose Combination of Travoprost 0.004% / Timolol Maleate 0.5% in Patients With Primary Open-angle Glaucoma or Ocular Hypertension
|
Phase 4 | |
| Completed |
NCT00397241 -
24-hour Study of Dorzolamide/Timolol and Latanoprost/Timolol Fixed Combinations
|
Phase 4 | |
| Completed |
NCT00918346 -
Pharmacodynamics of Tafluprost 0.0015% Eye Drops: a Comparison Between the Preserved and Unpreserved Formulation
|
Phase 3 | |
| Completed |
NCT00273481 -
Cosopt Versus Xalacom
|
Phase 4 | |
| Completed |
NCT00716742 -
Safety and Efficacy Study of Bimatoprost, Latanoprost, and Travoprost in Patients With Elevated Intraocular Pressure (IOP) and Open-angle Glaucoma (OAG)
|
N/A | |
| Completed |
NCT02558400 -
Double-masked Study of PG324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension
|
Phase 3 | |
| Withdrawn |
NCT03648229 -
African Glaucoma Laser Trial
|
Phase 4 | |
| Completed |
NCT01978600 -
Evaluation of Intraocular Pressure Using Simbrinza™ in Patients With Open-Angle Glaucoma or Ocular Hypertension
|
Phase 4 | |
| Completed |
NCT01699464 -
A Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-12286 in Patients With Elevated Intraocular Pressure for 3 Months
|
Phase 2 | |
| Completed |
NCT01464424 -
Assessment of Intraocular Pressure (IOP) Control in Subjects With Open-Angle Glaucoma or Ocular Hypertension Treated With Travoprost 0.004% (TRAVATAN® Z) or Bimatoprost 0.01% (LUMIGAN®)
|
Phase 4 |